Compare SQNS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | ANIX |
|---|---|---|
| Founded | 2003 | 1982 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 114.0M |
| IPO Year | 2011 | 2013 |
| Metric | SQNS | ANIX |
|---|---|---|
| Price | $2.94 | $2.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $20.33 | $8.67 |
| AVG Volume (30 Days) | 29.4K | ★ 332.0K |
| Earning Date | 05-05-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $49.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.38 | $2.32 |
| 52 Week High | $10.61 | $5.46 |
| Indicator | SQNS | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 34.84 |
| Support Level | $2.94 | $2.73 |
| Resistance Level | $3.20 | $3.09 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 71.83 | 16.36 |
Sequans Communications SA is a fabless semiconductor company specializing in wireless 4G and 5G cellular technologies for the Internet of Things (IoT). Sequans' engineers design and develop, secure, and energy-efficient semiconductor solutions that enable the next generation of AI-connected applications, including smart energy metering, industrial automation, smart mobility and logistics, secure payments, e-health, and smart home solutions. The Company offers a comprehensive portfolio of wireless connectivity solutions, including radio frequency (RF) transceivers, integrated circuits (ICs) for baseband processing, as well as modules, software, & protocol stacks. The Company has one operating segment, which is the design & marketing of semiconductor components for cellular wireless systems.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.